EQT Foundation的动态

We’re happy to share that the Institute of Pathology at Sheba Medical Center has been featured in The Cancer Letter! The article highlights our collaboration with Roche to use AI-powered digital pathology to transform diagnostics for non-small cell lung cancer (NSCLC). This initiative, spearheaded by Professor Iris Barshack, is paving the way for faster and more precise diagnostics, with the goal of improving outcomes for patients. Read more in the article: "Sheba Medical Center, Roche collaborate to transform NSCLC diagnostics with AI-powered digital pathology" in The Cancer Letter. #AI #DigitalPathology #NSCLC

Unlocking precision in cancer diagnostics! ?Our Cancer Diagnostic Probe (CDP) is revolutionizing the way we detect and treat cancer, offering faster and more accurate results than frozen pathology. Embrace the future of cancer detection with our innovative technology and experience improved patient outcomes. #CancerAwareness?#InnovativeTechnology?#PrecisionMedicine16:17

?? Qritive Joins Forces with Roche to Redefine Global Cancer Diagnostics with AI This collaboration represents a significant milestone to advance cancer diagnostics and treatment and accelerate adoption of AI by pathologists. With Qritive’s AI-powered solutions fully integrated with Roche navify??Digital Pathology platform, pathologists can leverage AI technology to diagnose cancer more accurately and efficiently, leading to reduced time to treatment and enhanced patient outcomes. These clinically validated AI modules, designed for colon, prostate, breast, and gastric cancers, analyze whole slide images to identify and grade tumor with precision. Read more online: https://lnkd.in/e3KFxxCf ?? Follow Medical Device Developments to receive the latest medical device news daily and to subscribe to our weekly newsletter #MedicalDeviceDevelopments #medicaldevices #medicalmanufacturing

“Their analysis suggests a robust and steady growth rate in the market sector from $1.55 billion to $2.34 billion in 2030 at a compound annual growth rate (CAGR) of 7.05%, underscoring the Company’s appropriate timing to pursue regulatory authorization and the strategic positioning of its first medical imaging device, IzoView- a disruptive device offering ultra-high-resolution, true 3D, dedicated breast CT imaging, indicated for breast cancer screening adjunctive to digital breast tomosynthesis (“DBT”, also known as 3D mammography) for patients with dense breast tissue.”

We've been featured in Research and Markets' announcement of their new U.S. #breastcancer analysis and forecast report! #DenseBreastTissue continues to be a high priority and digital breast tomosynthesis is holding strong with its 15-50 degree image acquisition that is providing increased #breastcancer detection over mammography. Our #BreastCT device #IzoView offers true 3D, 360-degree image acquisition and we can't wait to see what impact we could have in the breast cancer screening and diagnostic device sales market in the future. https://loom.ly/x4yF78A $IZO $IZOZF

Streamlining Cancer Diagnostics in Pathology! ?? New advancements are revolutionizing cancer diagnostics, enhancing precision and efficiency in pathology labs. ?? These technologies promise faster, more accurate results, improving patient care and outcomes. A leap forward in cancer management! ?? Sakura Finetek Europe MEDIPATH FRANCE Know complete story - https://lnkd.in/dJ5yhp74 #CancerDiagnostics #PathologyInnovation #HealthcareAdvances #MedicalBreakthrough

?? Innovative Advancement in Breast Cancer Care! ?? In our latest video, Professor Catherine Guettier, Head of the Pathology Department at H?pital Bicètre AP-HP, shares insights on the groundbreaking RlapsRisk? BC algorithm developed by Owkin. This AI-driven tool is revolutionizing how we predict the risk of recurrence in ER+/HER2- breast cancer patients right from the moment of diagnosis! ?? By utilizing digitized slides and our CaloPix? imaging management system, this innovation empowers pathologists and oncologists to make more informed treatment decisions, ultimately improving patient outcomes. ???? Discover how artificial intelligence is transforming breast cancer diagnosis and care. Watch the video and learn more about this promising advancement! ?? #DigitalPathology #RlapsRiskBC #BreastCancer #PrecisionMedicine #TribunHealth

CircRNAs provide a promising avenue for non-invasive testing and molecular characterization, while IHC remains a cornerstone of traditional cancer pathology. The article "Circular RNAs in Breast Cancer: Diagnosis, Treatment, and Prognosis," demonstrated how circRNAs can help in the early detection of breast cancer due to their stability in body fluids and specific expression patterns in cancerous tissues. Monitoring circRNA levels could help predict disease progression and patient survival. Read the full article here: https://buff.ly/4f9U1Ud

Tumor-infiltrating lymphocytes serve as both biomarkers of tumor microenvironment dynamics and indicators of anti-tumor immunity. The integration of AI in pathology offers unprecedented precision, enabling deep-learning algorithms to enhance prognostic assessment and clinical decisions in triple-negative breast cancer. Read the full article here: https://lnkd.in/ggdNw_u4

We've been name-dropped. Izotropic was listed in Research and Markets announcement and description of a new research report on the U.S. Breast Cancer Screening and Diagnostic Market ?? https://loom.ly/H7x_2mc "Their analysis suggests a robust and steady growth rate in the market sector from $1.55 billion to $2.34 billion in 2030 at a compound annual growth rate (CAGR) of 7.05%, underscoring the Company’s appropriate timing to pursue regulatory authorization and the strategic positioning of its first medical imaging device, IzoView- a disruptive device offering ultra-high-resolution, true 3D, dedicated breast CT imaging, indicated for breast cancer screening adjunctive to digital breast tomosynthesis for patients with dense breast tissue." ?? https://loom.ly/9WtTKws #medtech #investing #stocks #stocktowatch